Skip to NavigationSkip to content

AI

Key legal considerations in accelerating pharma using artificial intelligence

Published on 04/09/19 at 12:55pm

Charlotte Walker-Osborn, Partner and International Technology Sector Head and Nabil Asaad, Senior Associate, Intellectual Property Law Group – both from global law firm Eversheds Sutherland – discuss the intricacies of pharma/AI partnerships, including data privacy, cyber security, and intellectual property concerns.

Recent advances in the development of artificial intelligence (AI), coupled with the availability of sufficient computing power to enable their effective use, have now made the application of AI methods to pharmaceutical R&D a realistic prospect.

Finding the needle in the haystack of rare disease

Published on 19/08/19 at 11:53am

Through the use of Genomenon’s AI-driven Mastermind Genomic Search Engine, the Rare Genomics Institute succeeded where a leading genetics laboratory had failed in securing diagnosis for an ultra-rare disease patient. Romina Ortiz, Chief Operating Officer and Vice President, Patient Advocacy at the Institute explains how the platform could prove transformative in tackling the challenges of ultra-rare disease diagnosis.

Rare genetic diseases pose a challenge for diagnosis in three ways.

Top Ten most popular articles on Pharmafile.com this week!

This week’s top story covered the scandal surrounding Novartis over its covering up of faulty data from the FDA. The Swiss firm’s integrity was called into question after it waited until it’s $2.1 million gene therapy had been approved before informing the US regulator of inaccuracies in its data.

AI accurately detects subtle signs of atrial fibrillation even in normal tests

A new study from the Mayo Clinic shows that artificial intelligence (AI) can detect signs of atrial fibrillation (AF) in an electrocardiogram (EKG), even if the heart is in a normal rhythm at the time of the test.

AI better than radiologists at diagnosing lung cancer

An artificial intelligence (AI) is better than specialist doctors at diagnosing lung cancer, according to a study from researchers at Google and Northwestern University in Illinois.

While not yet ready for clinical use, it is hoped that the technology will boost the effectiveness of cancer screening in the future.

The study, published in the journal Nature Medicine, outlines a deep learning algorithm that is able to predict a patient’s risk of lung cancer.

Merck KGaA enters drug discovery partnership with AI firm Itkos

Merck KGaA and artificial intelligence (AI) firm Iktos have entered into a partnership, the pair have announced, to leverage the latter’s generative modelling AI technology in a bid to “facilitate the rapid and cost-effective discovery and design of promising new compounds”.

The firm’s AI technology, which is based on “deep generative models”, promises to “bring speed and efficiency to the drug discovery process” by quickly singling out molecules which satisfy the requirements of multiple bioactivity and drug-like criteria for clinical testing.

Solving the drug development problem

Published on 11/02/19 at 01:06pm

Excitement is building for the potential of AI in just about every field, but how can it address pharma’s unique challenges? Matt Fellows speaks to the not-for-profit organisation the Pistoia Alliance to see where the industry identifies these challenges, and how the technology can help tackle them.

Drug discovery is in crisis.

Read Pharmafocus January/February 2019 edition online now!

We’re slowly edging towards warmer months, but the New Year brings more than just the promise of more amicable weather; in a manner reminiscent of past years, industry M&A is off to an explosive start, as multinational drug firm Bristol-Myers Squibb announced within the first days of the year that it had entered into an agreement to acquire Celgene for approximately $74 billion – the biggest pharma acquisition ever.

Kyowa Hakko Kirin signs drug discovery deal with AI firm InveniAI

Japanese pharma and biotech firm Kyowa Hakko Kirin is joining the growing trend of investing in artificial intelligence to bolster drug discovery efforts, entering a new partnership with AI and machine learning firm InveniAI.

KHK hopes to utilise InveniAI’s AlphaMeld technology to discover how its existing pipeline products can be applied to other indications.

While the exact financial details of the deal were not disclosed, it was confirmed that an upfront sum will be paid to InveniAI, as well as a number of development and commercialisation payments.

UK-Japan partnership to see collaboration on incurable diseases, green technology and AI

A new partnership between the UK and Japan will see medical researchers and scientists join forces, in advancing research into chronic conditions - such as diabetes, heart disease and arthritis - green technology and AI.

The collaboration, announced by British Prime Minister Theresa May, Business Secretary Greg Clark and Japanese Prime Minister Shinzo Abe, will see £30 million invested into a new partnership aimed at promoting technology and innovation in both Britain and Japan.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches